Industry News (Patents and Technologies)

U.S. Patent on 3TC Awarded to Emory University

Published in Hepatitis Weekly, August 5th, 1996

The U.S. Patent and Trademark Office (PTO) awarded the patent on the antiviral drug 3TC to Emory University in Atlanta, Georgia.

3TC (also known as Epivir or lamivudine) is an important component of the new AIDS "cocktail" therapies, in which two or more drugs which exert different kinds of selective pressures on the virus are administered together. 3TC was approved by the U.S. Food and Drug Administration (FDA) for marketing and sale on November 17, 1995, in combination with AZT for the treatment of HIV and AIDS as a "first line" therapy.

3TC also is now in clinical trials for the treatment of hepatitis B virus (HBV) in the United States, Japan,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1996-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry